Abstract
We present dosimetry for spinal metastases and red bone marrow in two patients who received 89Sr therapy for disseminated prostatic carcinoma. Absorbed dose to metastases was estimated by combining 85Sr gamma camera studies with computed tomographic measurements of bone mass, and doses of 20 cGy/MBq and 24 cGy/MBq were found for vertebral metastases that uniformly involved the bodies of L3 and D12 respectively. Absorbed dose to red bone marrow was estimated from total body strontium retention studies using the ICRP model for bone dosimetry, and a ratio of metastatic to marrow dose of around 10 was found in each patient. Although they received comparable treatment activities of around 200 MBq, the patients showed markedly different haematological response, this difference being confirmed when each received a second 89Sr treatment 6 months after the first. As a result, clinically significant thrombocytopenia occurred in one patient which prevented further radiostrontium therapy being given.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blake GM, Zivanovic MA, McEwan AJ, Ackery DM (1986) 89Sr therapy:-strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447–454
Blake GM, Gray JM, Zivanovic MA, McEwan AJ, Fleming JS, Ackery DM (1987) 89Sr radionuclide therapy:-a dosimetric study using impulse response function analysis. Br J Radiol (in press)
Cross WG, Ing H, Freedman N (1983) A short atlas of beta-ray spectra. Phys Med Biol 28:1251–1260
Eisenhut M, Berberich R, Kimmig B, Oberhausen E (1986) Iodine-131 labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3. J Nucl Med 27:1255–1261
Firusian N, Mellin P, Schmidt CG (1976) Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol 116:764–768
Genant HK, Cann CE, Ettinger B, Gordan GS, Kolb FO, Reiser U, Claude DA (1985) Quantitative computed tomography for spinal mineral assessment: current status. J Comput Assist Tomogr 9:602–604
Goeckeler WF, Edwards B, Volkert WA, Troutner DE, Holmes RA, Simon J, Wilson D (1986) Biolocalization properties of Sm-153 chelates as radiotherapeutic bone agents. J Nucl Med 27:915 (abstr)
Gong JK, Burgess E, Bacalao P (1966) Accretion and exchange of strontium-85 in trabecular and cortical bones. Radiat Res 28:753–765
ICRP (1975) ICRP Publication 23: Report of the task group on reference man. Pergamon Press, Oxford
ICRP (1979) Dosimetric model for bone. In: ICRP Publication 30: Limits for intakes of radionuclides by workers. Part 1, pp 35–46. Pergamon Press, Oxford
Marshall JH, Lloyd EL, Rundo J, Liniecki J, Marroti G, Mays CW, Sissons HA, Snyder WS (1973) Alkaline earth metabolism in adult man. Health Phys 24:125–221
Maxon HR, Deutsch E, Libson K, Williams C, Thomas S, Lukes S, Chen IW (1986) 186Re(Sn)HEDP:-a new agent for diagnosis and treatment of metastatic carcinoma to bone. J Nucl Med 27:948 (abstr)
McEwan AJ, Zivanovic MA, Blake GM, Buchanan RB, Ackery DM (1986) Sr-89 Therapy: clinical response in metastatatic bone disease. Nucl Med Commun 7:293 (abstr)
Pecher C (1942) Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of bone cancer. Univ Calif Publ Pharmacology 11:117–149
Reeve J, Hesp R (1976) A model-independent comparison of the rates of uptake and short term retention of 47Ca and 85Sr in the skeleton. Calcif Tissue Res 22:183–189
Robinson RG (1986) Radionuclides for the alleviation of bone pain in advanced malignancy. Clin Oncol 5:39–49
Silberstein EB, Williams C (1985) Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 26:345–348
Sudell CJ, Blake GM, Gossage AAR, Cullen DR, Munro DS (1985) Adrenal scintigraphy with 75Se selenonorcholestenol: a review. Nucl Med Commun 6:519–527
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blake, G.M., Zivanovic, M.A., McEwan, A.J. et al. 89Sr radionuclide therapy: Dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Eur J Nucl Med 13, 41–46 (1987). https://doi.org/10.1007/BF00252645
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00252645